Health Establishment Begin to Accept Hydroxychloroquine as COVID Treatment With New Study
A new study shows that the hotly contested anti-malarial drug hydroxychloroquine (HCQ) along with zinc is effective against COVID-19. This study appears to be getting national attention after the hysteria about the pandemic has seemed to subside.
The observational study, published by medRxiv, found HCQ, along with zinc, could increase the coronavirus survival rate by as much as nearly 200% if distributed at higher doses to ventilated patients with a severe version of the illness. These patients had notoriously low survival rates and it was previously thought that no therapy helped.
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study’s conclusion states.
The study adds, “By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot.”
The study was conducted by Saint Barnabas Medical Center in New Jersey on 255 patients.
During the pandemic, other generic drugs such as ivermectin showed promise in treating COVID-19 while the health establishment promoted ineffective treatments such as Remdesivir.
